The company received the US FDA’s clearance on the IND application submitted for ACE2016 based on the preclinical results depicting the effects of ACE2016 in solid tumor models
Following the US FDA’s clearance, Acepodia expects to initiate a P-I FIH trial evaluation the safety, efficacy, tolerability & PD of ACE2016 in patients with locally advanced or metastatic EGFR-expressing solid tumors. The first patient dosing is expected by H2’24
ACE2016 is an allogenic γδ2 T cell therapy candidate developed using the company’s proprietary ACC platform to target EGFR-expressing solid tumors through antibody conjugated γδ2 T cells
Ref: PR Newswire | Image: Acepodia
Related News:- AstraZeneca and Daiichi Sankyo Reports sBLA Acceptance with Priority Review by the US FDA for Enhertu to Treat HER2-Expressing Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
